CANbridge Pharmaceuticals Inc. (1228.HK)
HKD 0.16
(0.65%)
HKD 0.16
(0.65%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -341.42 Million CNY | 24.92% |
| 2022 | -454.63 Million CNY | 58.72% |
| 2021 | -1.05 Billion CNY | -37.17% |
| 2020 | -824.41 Million CNY | -277.81% |
| 2019 | -212.73 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -106.48 Million CNY | 0.0% |
| 2024 Q1 | -106.48 Million CNY | -35.53% |
| 2023 Q3 | -78.56 Million HKD | 20.47% |
| 2023 FY | - CNY | 24.92% |
| 2023 Q2 | -98.79 Million CNY | 0.0% |
| 2023 Q1 | -98.79 Million CNY | 9.75% |
| 2023 Q4 | -78.56 Million CNY | 0.0% |
| 2022 Q2 | -114.96 Million CNY | 0.0% |
| 2022 Q1 | -114.96 Million CNY | 19.36% |
| 2022 FY | - CNY | 58.72% |
| 2022 Q4 | -109.46 Million CNY | 0.0% |
| 2022 Q3 | -109.46 Million CNY | 4.79% |
| 2021 Q1 | -101.07 Million CNY | -44.97% |
| 2021 FY | - CNY | -37.17% |
| 2021 Q4 | -142.57 Million CNY | 0.0% |
| 2021 Q3 | -142.57 Million CNY | 45.14% |
| 2021 Q2 | -259.89 Million CNY | -157.14% |
| 2020 Q4 | -69.71 Million CNY | 0.0% |
| 2020 Q2 | -49.2 Million CNY | -72.74% |
| 2020 Q3 | -69.71 Million CNY | -41.69% |
| 2020 Q1 | -28.48 Million CNY | 0.0% |
| 2020 FY | - CNY | -277.81% |
| 2019 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 474.234% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 170.138% |